5% vs.
2.5%,P-value for trend < .04).[20][Level of evidence B3] Aromatase inhibitors (AIs) have also been compared with tamoxifen in the preoperative setting.
Overall objective response and breast-conserving therapy rates with 3 to 4 months of preoperative therapy were either statistically significantly improved in the AI-treated women [18] or comparable to tamoxifen-associated outcomes.[20] The use of preoperative endocrine therapy in premenopausal women with hormone-responsive breast cancer remains investigational.
Stage and molecular features determine the need for adjuvant systemic therapy and the choice of modalities for patients who have not been treated with preoperative systemic therapy.